Amarin Introduces Ratio Change for American Depositary Shares
Amarin Corporation plc (NASDAQ: AMRN) has announced an important update concerning its American Depositary Shares (ADSs). The company plans to change the current structure of its ADSs from representing one ordinary share to a new ratio of one ADS equivalent to twenty ordinary shares. This adjustment, known as the Ratio Change, aims to enhance the market price of Amarin's shares and align with Nasdaq's requirement for a minimum bid price.
The Objectives Behind the Ratio Change
The primary motivation for this Ratio Change is to bolster the price potential of Amarin's ADSs. Compliance with Nasdaq's minimum bid price, currently set at $1.00 per share, is crucial for maintaining the company's listings. The anticipated date for this change is on or about April 11, 2025, where adjustments will occur automatically for holders of uncertificated ADSs in the Direct Registration System (DRS) and the Depository Trust Company (DTC).
Implications for Shareholders
Holders of ADSs will not need to take any action as the conversion from twenty existing ADSs to one new ADS will happen seamlessly. However, those with certificated ADSs will have to surrender their current certificates to receive their new ADS representation. It’s significant to note that this change does not entail the issuance of fractional new ADSs. Any fractional entitlements will be aggregated and sold, with the resulting cash distributed to the current ADS holders by the depositary bank.
Market Expectations Following the Change
While the Ratio Change is projected to enhance the trading price of Amarin's ADSs, the company has established no guarantees regarding the post-adjustment trading price. Investors are encouraged to be aware of this change, as it has the potential to impact the trading landscape significantly.
Understanding Amarin and Its Mission
Amarin is a pioneering pharmaceutical company that is advancing the treatment landscape for cardiovascular disease management. With a commitment to improving scientific knowledge of cardiovascular risks that extend beyond conventional therapies, Amarin is at the forefront of transforming patient care worldwide. The company operates from multiple locations including Bridgewater, New Jersey, and Dublin, Ireland, with additional offices in Zug, Switzerland and partnerships across Europe.
Where to Find More Information
Those seeking additional clarity on the Ratio Change are encouraged to explore the Investor Relations section on Amarin's corporate website. This platform provides a wealth of resources, including FAQs and investor presentations, which can enhance understanding for existing and prospective investors alike.
Frequently Asked Questions
What is the Ratio Change for Amarin's ADSs?
The Ratio Change involves converting one ADS to represent twenty ordinary shares, aiming to increase the ADS market price.
When will the Ratio Change take effect?
The proposed effective date for the Ratio Change is on or about April 11, 2025.
Will current shareholders need to take any action?
Holders of uncertificated ADSs will not need to take action, while certificated holders must surrender their certificates for the new ADS.
How will fractional ADSs be handled?
Fractional entitlements will be sold, and the proceeds will be distributed to shareholders.
What are the expectations for ADS trading prices after the change?
While a proportional increase in trading prices is expected, there are no guarantees that the price will be twentyfold the previous value.
